MX2015008766A - Compuestos cbd fluorados, composiciones y usos de los mismos. - Google Patents
Compuestos cbd fluorados, composiciones y usos de los mismos.Info
- Publication number
- MX2015008766A MX2015008766A MX2015008766A MX2015008766A MX2015008766A MX 2015008766 A MX2015008766 A MX 2015008766A MX 2015008766 A MX2015008766 A MX 2015008766A MX 2015008766 A MX2015008766 A MX 2015008766A MX 2015008766 A MX2015008766 A MX 2015008766A
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- cbd compounds
- fluorinated
- compounds
- fluorinated cbd
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/055—Phenols the aromatic ring being substituted by halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/373—Halogenated derivatives with all hydroxy groups on non-condensed rings and with unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
- C07C39/24—Halogenated derivatives
- C07C39/42—Halogenated derivatives containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/16—Acetic acid esters of dihydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/62—Halogen-containing esters
- C07C69/63—Halogen-containing esters of saturated acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Abstract
La presente invención se relaciona con compuestos de CBD sustituidos con flúor, composiciones de los mismos y usos de los mismos para la preparación de medicamentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361750043P | 2013-01-08 | 2013-01-08 | |
PCT/IL2014/050023 WO2014108899A1 (en) | 2013-01-08 | 2014-01-08 | Fluorinated cbd compounds, compositions and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015008766A true MX2015008766A (es) | 2016-03-07 |
Family
ID=50272668
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015008766A MX2015008766A (es) | 2013-01-08 | 2014-01-08 | Compuestos cbd fluorados, composiciones y usos de los mismos. |
Country Status (10)
Country | Link |
---|---|
US (3) | US9447019B2 (es) |
EP (1) | EP2943463B1 (es) |
JP (3) | JP6228230B2 (es) |
CN (1) | CN105209424B (es) |
AU (2) | AU2014206036B2 (es) |
CA (1) | CA2935899C (es) |
ES (1) | ES2894836T3 (es) |
HK (1) | HK1214586A1 (es) |
MX (1) | MX2015008766A (es) |
WO (1) | WO2014108899A1 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6228230B2 (ja) * | 2013-01-08 | 2017-11-08 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッドYissum Research Development Company Of The Hebrew Universty Of Jerusalem Ltd. | フッ化cbd化合物、それらの組成物および使用 |
US20190084909A1 (en) * | 2015-07-16 | 2019-03-21 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Fluorinated cbd compounds, compositions and uses thereof |
EP3352855A4 (en) | 2015-09-22 | 2019-05-22 | Vitality Biopharma, Inc. | CANNABINOID GLYCOSIDE PRODRUGS AND METHODS OF SYNTHESIS |
JP2018534362A (ja) * | 2015-10-16 | 2018-11-22 | スキティアン バイオサイエンシーズ インコーポレーテッドScythian Biosciences Inc. | 外傷性脳損傷を処置するための方法および組成物 |
US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
CA3063186A1 (en) | 2017-05-09 | 2018-11-15 | Vitality Biopharma, Inc. | Antimicrobial compositions comprising cannabinoids and methods of using the same |
AU2018275687A1 (en) | 2017-05-31 | 2020-01-02 | Phytecs, Inc. | Pharmaceutical compositions comprising cannabidiol and beta-caryophyllene and methods for their use |
DK3687513T3 (da) | 2017-09-28 | 2022-03-07 | Zynerba Pharmaceuticals Inc | Behandling af fragilt x-syndrom og autisme med cannabidiol |
WO2019152736A1 (en) | 2018-01-31 | 2019-08-08 | Canopy Holdings, LLC | Hemp powder |
CA3163788A1 (en) | 2019-12-06 | 2021-06-10 | JLABS Beauty LLC | Topical compositions containing rose oil and cannabidiol and methods of making and using the same |
GB202002754D0 (en) | 2020-02-27 | 2020-04-15 | Gw Res Ltd | Methods of treating tuberous sclerosis complex with cannabidiol and everolimus |
EP4153306A1 (en) | 2020-05-22 | 2023-03-29 | Ilera Derm LLC | Compositions for treating acne and dermatological conditions |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566560B2 (en) | 1999-03-22 | 2003-05-20 | Immugen Pharmaceuticals, Inc. | Resorcinolic compounds |
EP2176208B1 (en) * | 2007-07-30 | 2015-01-21 | Zynerba Pharmaceuticals, Inc. | Prodrugs of cannabidiol, compositions comprising prodrugs of cannabidiol and methods of using the same |
US20120172339A1 (en) | 2009-07-10 | 2012-07-05 | Northeastern University | Angiogenic resorcinol derivatives |
US20110052694A1 (en) * | 2009-08-31 | 2011-03-03 | Alltranz Inc. | Use of cannabidiol prodrugs in topical and transdermal administration with microneedles |
WO2012011112A1 (en) * | 2010-07-22 | 2012-01-26 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Non psychoactive cannabinoids and uses thereof |
JP6228230B2 (ja) | 2013-01-08 | 2017-11-08 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッドYissum Research Development Company Of The Hebrew Universty Of Jerusalem Ltd. | フッ化cbd化合物、それらの組成物および使用 |
-
2014
- 2014-01-08 JP JP2015551255A patent/JP6228230B2/ja active Active
- 2014-01-08 WO PCT/IL2014/050023 patent/WO2014108899A1/en active Application Filing
- 2014-01-08 AU AU2014206036A patent/AU2014206036B2/en active Active
- 2014-01-08 CN CN201480012168.2A patent/CN105209424B/zh active Active
- 2014-01-08 ES ES14709750T patent/ES2894836T3/es active Active
- 2014-01-08 CA CA2935899A patent/CA2935899C/en active Active
- 2014-01-08 US US14/759,689 patent/US9447019B2/en active Active
- 2014-01-08 EP EP14709750.5A patent/EP2943463B1/en active Active
- 2014-01-08 MX MX2015008766A patent/MX2015008766A/es unknown
-
2016
- 2016-03-01 HK HK16102360.0A patent/HK1214586A1/zh unknown
- 2016-08-19 US US15/241,557 patent/US9782360B2/en active Active
-
2017
- 2017-08-01 US US15/666,128 patent/US10441553B2/en active Active
- 2017-10-12 JP JP2017198146A patent/JP2018065794A/ja active Pending
-
2018
- 2018-01-24 AU AU2018200570A patent/AU2018200570B2/en active Active
-
2019
- 2019-01-28 JP JP2019012349A patent/JP6952727B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
HK1214586A1 (zh) | 2016-07-29 |
CA2935899C (en) | 2021-08-31 |
ES2894836T3 (es) | 2022-02-16 |
WO2014108899A1 (en) | 2014-07-17 |
CN105209424B (zh) | 2019-12-13 |
US20150344403A1 (en) | 2015-12-03 |
AU2014206036B2 (en) | 2017-11-02 |
CN105209424A (zh) | 2015-12-30 |
JP2018065794A (ja) | 2018-04-26 |
JP6228230B2 (ja) | 2017-11-08 |
AU2014206036A2 (en) | 2016-06-16 |
US9447019B2 (en) | 2016-09-20 |
AU2018200570B2 (en) | 2019-09-26 |
CA2935899A1 (en) | 2014-07-17 |
US20170326078A1 (en) | 2017-11-16 |
US9782360B2 (en) | 2017-10-10 |
AU2014206036A1 (en) | 2015-08-13 |
US10441553B2 (en) | 2019-10-15 |
EP2943463A1 (en) | 2015-11-18 |
JP6952727B2 (ja) | 2021-10-20 |
AU2018200570A1 (en) | 2018-02-15 |
JP2016505614A (ja) | 2016-02-25 |
EP2943463B1 (en) | 2021-07-14 |
JP2019073547A (ja) | 2019-05-16 |
US20170197904A1 (en) | 2017-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015008766A (es) | Compuestos cbd fluorados, composiciones y usos de los mismos. | |
PH12016501151A1 (en) | Nrf2 regulators | |
UA116467C2 (uk) | Модулятори p2x7 | |
IL245184A0 (en) | Prostacyclin compounds, preparations and methods of using them | |
PH12014502697A1 (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
NZ716840A (en) | Combination formulation of two antiviral compounds | |
MX2017004617A (es) | Variantes estabilizadas de alfa amilasa y su uso. | |
EA201590887A1 (ru) | Композиция | |
MX2020001756A (es) | Compuestos deuterados del inhibidor vmat y el uso de dichos compuestos. | |
MX2018000515A (es) | Compuestos fluorados de cbd, composiciones y usos de los mismos. | |
MX345926B (es) | Nuevas composiciones, producción de las mismas y uso de las mismas para la producción de poliamidas coladas. | |
MX364069B (es) | Moduladores de la proteína activadora de 5-lipoxigenasa. | |
AU2018253594A1 (en) | Dihydroxyphenyl neurotransmitter compounds, compositions and methods | |
IN2013MU03641A (es) | ||
MX2015016603A (es) | Composiciones de corticosteroides. | |
WO2014172363A3 (en) | Combretastatin analogs | |
PH12015502703A1 (en) | Pharmaceutical compositions | |
MX2015009377A (es) | Compuestos radiomarcados. | |
EA201692453A1 (ru) | Способ получения ингаляционных составов | |
EA201591770A1 (ru) | Таксоиды - принцип очистки для жидких наполнителей | |
IN2013MU03768A (es) | ||
MX2017005669A (es) | Derivados de hidroxido de bencilo, preparacion de los mismos y uso terapeutico de los mismos. | |
UA91886U (uk) | 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол | |
WO2014113427A3 (en) | Irciniastatin analogues | |
IN2013CH00453A (es) |